PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
16360124-6	2006	These results suggest that the desensitization of 5-HT2A receptor function occurs in the same way as that of 5-HT2C receptor function through chronic treatment with either fluvoxamine or paroxetine as a consequence of prolonged exposure to elevated levels of serotonin.	Fluvoxamine	172-183	5-hydroxytryptamine receptor 2C	Rattus norvegicus	109-115	
15301922-0	2004	Chronic treatment with fluvoxamine desensitizes 5-HT2C receptor-mediated hypolocomotion in rats.	Fluvoxamine	23-34	5-hydroxytryptamine receptor 2C	Rattus norvegicus	48-54	
15301922-3	2004	In the present study, we investigated whether chronic administration of fluvoxamine desensitizes 5-HT2C receptors using a putative in vivo rat model of 5-HT2C receptor function.	Fluvoxamine	72-83	5-hydroxytryptamine receptor 2C	Rattus norvegicus	97-103	
15301922-3	2004	In the present study, we investigated whether chronic administration of fluvoxamine desensitizes 5-HT2C receptors using a putative in vivo rat model of 5-HT2C receptor function.	Fluvoxamine	72-83	5-hydroxytryptamine receptor 2C	Rattus norvegicus	152-158	
15301922-5	2004	This effect of fluvoxamine was reversed by treatment with a selective 5-HT2C receptor antagonist, SB 242084.	Fluvoxamine	15-26	5-hydroxytryptamine receptor 2C	Rattus norvegicus	70-76	
15301922-8	2004	These results suggest that 5-HT2C receptors are desensitized by chronic treatment with fluvoxamine, as well as paroxetine.	Fluvoxamine	87-98	5-hydroxytryptamine receptor 2C	Rattus norvegicus	27-33	
15301922-9	2004	Thus, the clinical efficacy of fluvoxamine on anxiety disorders might involve the normalization of the 5-HT2C receptor function.	Fluvoxamine	31-42	5-hydroxytryptamine receptor 2C	Rattus norvegicus	103-109